about
Drug mechanisms to help in managing resistant hypertension in obesityMolecular genetics and gene expression in atherosclerosis.Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation.The relationship between walking speed and changes in cardiovascular risk factors during a 12-day walking tour to Santiago de Compostela: a cohort study.Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.Mechanisms linking obesity to hypertension.The cardiovascular polypill in high-risk patients.The Arg16Gly variant of the beta2-adrenergic receptor predisposes to hypoglycemia unawareness in type 1 diabetes mellitus.Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.Vascular and metabolic effects of 12 days intensive walking to Santiago de Compostela.The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide.Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: first results of the Hippocates study.Feasibility and reproducibility of free fatty acid profiling in abdominal adipose tissue with 1H-magnetic resonance spectroscopy at 3 T: differences between lean and obese individuals.[Renal artery stenosis: do not toss the stent aside].The risk of resting heart rate on vascular events and mortality in vascular patients.The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease.Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade.The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.Metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease.Relation between abdominal obesity, insulin resistance and left ventricular hypertrophy diagnosed by electrocardiogram and magnetic resonance imaging in hypertensive patients.Risk of elevated resting heart rate on the development of type 2 diabetes in patients with clinically manifest vascular diseases.Increased visceral adipose tissue is associated with increased resting heart rate in patients with manifest vascular disease.Relation between adiposity and hypertension persists after onset of clinically manifest arterial disease.A116C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited.High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study.Dissociation between the renal effects of angiotensin I and II in sodium-restricted normal subjects.The way to a man's stomach is through his heart? the relation between natriuretic peptide levels and adipose tissue distribution.Alpha-adducin Gly460Trp polymorphism and renal hemodynamics in essential hypertension.Long-QT syndrome induced by the antiaddiction drug ibogaine.The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence riskThe Evening versus Morning Polypill Utilization Study: the TEMPUS rationale and designMeasuring Free-Living Physical Activity With Three Commercially Available Activity Monitors for Telemonitoring Purposes: Validation StudyHepatosplenic gammadelta T-cell lymphoma: A case reportGenetic influences on 24 h blood pressure profiles in a hypertensive population: role of the angiotensin-converting enzyme insertion/deletion and angiotensin II type 1 receptor A1166C gene polymorphismsDifferences in determinants of left ventricular mass assessed by cardiac magnetic resonance imaging across subjects with and without previous symptomatic atherosclerotic disease[Cardiovascular polypill in high risk patients]Polymorphisms in human connexin40 gene promoter are associated with increased risk of hypertension in menPrediction of cerebral hyperperfusion after carotid endarterectomy with transcranial Doppler
P50
Q34023578-3B86686E-51B2-45BD-B19E-3BF824FAAC56Q34386072-69B2B7D7-E20E-4934-90A1-975C347B3DACQ34495057-CF94C2C7-B805-43C1-A2D3-FCFA3ABF8137Q35963055-04FCC325-0701-40B4-9D23-2AE4FE3D553AQ37303915-07051E5C-A6A9-46C0-8894-2B620C85F173Q37914949-5B11CA3C-41E9-4153-98F4-601004459062Q37948516-29B7D0FE-4E6F-4192-AE19-A84ED9980535Q40114545-0B04CCAC-65CA-4B0C-8D89-D75A131E811DQ40124148-CCE26F17-4E5D-44F9-BEBE-76654C7BD9C1Q42991227-A554C608-9D4D-455E-B618-5F3CD9414841Q44164789-49F4734D-3EBC-47B1-AD23-EC3AD7BAB9FAQ44289108-C858FD63-E351-4A8C-910A-5BB81A3ED90FQ44478301-9A0E80D1-9F7A-44C4-A0B8-771085AC3299Q44513081-69F603BA-1B28-4F64-B67B-B57663DD5E69Q44988195-45D2AEF1-B9F5-47BD-ABCF-9BE4D0319A4DQ46135770-8B10634E-62BA-4DA1-8B6E-8E144713B748Q46172660-F6740679-5BC6-466F-95B2-43EC0A1D4F80Q46388237-B2999112-8E65-4BC1-ADFA-017EC62DCB15Q46407139-2FEBB386-4B59-4C96-81CE-89786C6EC11DQ46553599-E5EB8333-2E34-44B4-915B-D6E7DF539BD2Q46648063-A17F4BAD-DD82-4581-995E-3D5FB3A694F3Q46711830-9E740ED2-0A08-4DDF-99F7-715AD7820D8FQ46790691-DEC0CACF-9AF4-4A8E-887B-2748CD7CD95CQ46792753-E8E14159-3F0D-4CFA-81F1-49202F7813B5Q46798253-05FC27E6-206F-42C9-BF97-77E1585384F1Q46881479-67508261-E167-46C8-B6A9-8DEFD533CFE6Q46938424-4C14D12E-3233-404D-A3DB-74842808E698Q47767203-0E078AE0-7CE6-4E0A-A211-357648CD362DQ51058206-EE754A60-E89D-43BD-8436-FCD963B92A54Q53887659-1BCB5B87-01AB-43B3-B0BF-999479EE668DQ55051326-8B62970E-FD82-4B19-BE17-72236A5CCC15Q57316357-83CC7CC9-905A-4D05-BCAB-B03C8E45BAB1Q57583148-236F1043-4B6B-441B-A309-8A0292FA2932Q63865934-AAB4A6ED-5B37-491D-BF8E-7F1FA27E5E65Q80194363-E953F8EC-5A42-483F-A234-AD2B43286B0CQ81796682-74451AB2-BC15-444F-BD8D-6C761FBCFFC9Q82011412-5A49F7F8-AD48-4C6F-897B-C8A1E3AB2785Q82428410-A655D080-3979-4C36-A98F-ACE26B859204Q82689615-CAD44B1D-8B8D-4EEC-BC04-DF70E25AD2EAQ83294213-8441CEA5-69AD-4497-AC6E-E0B11E5823D6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Wilko Spiering
@ast
Wilko Spiering
@en
Wilko Spiering
@es
Wilko Spiering
@nl
Wilko Spiering
@sl
type
label
Wilko Spiering
@ast
Wilko Spiering
@en
Wilko Spiering
@es
Wilko Spiering
@nl
Wilko Spiering
@sl
prefLabel
Wilko Spiering
@ast
Wilko Spiering
@en
Wilko Spiering
@es
Wilko Spiering
@nl
Wilko Spiering
@sl
P106
P1153
6603180845
P31
P496
0000-0002-2493-6407